ArticleBMC nephrology2026
Urinary extracellular vesicles levels of n-3 and n-6 polyunsaturated fatty acids in children with steroid-sensitive nephrotic syndrome: a pilot study.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundUrine extracellular vesicles (uEVs) are a useful source of non-invasive biomarkers for the diagnosis of kidney diseases. This study aims to characterize the fatty acid (FA) profile of uEVs in children with steroid-sensitive nephrotic syndrome (SSNS) during the active phase of the disease and remission, and to evaluate their association with a pro-inflammatory milieu.
methodsWe enrolled 35 SSNS children at different clinical stages, 10 SRNS children with proteinuria, and 14 healthy controls, and collected urine samples. uEVs were isolated by ultracentrifugation and characterized by Western blot, Nanoparticle Tracking Analysis, and Transmission Electron Microscopy. Lipid composition was evaluated by gas chromatography.
resultsAn increase in omega-3 fatty acids was observed in uEVs isolated from SSNS with proteinuria (above 0.2 mg/mg) (p < 0.01) or in remission (p < 0.05) compared to controls. The α-Linolenic acid (ALA) pathway changed in SSNS children compared to healthy controls. In detail, ALA was upregulated in SSNS patients at remission (p < 0.01 vs. CTRL). Its downstream products, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), were upregulated during remission (p < 0.01 vs. CTRL) and active disease phase (p < 0.05 vs. CTRL), respectively. A higher EPA/DHA ratio was detected in remission compared to the active disease phase (p < 0.05). Moreover, a reduction of linoleic acid (LA) was detected in SSNS at remission (p < 0.05 vs. active SSNS and SRNS) along with a lower linoleic acid/arachidonic acid ratio (LA/AA) (p < 0.01). Short-term prednisone treatment in relapsing patients did not significantly change the overall FA profile in uEVs.
conclusionsThis study provides the first evidence that uEV-associated FAs are differentially modulated in uEVs isolated from SSNS, compared to healthy children. Distinct lipid signatures characterize SSNS across disease stages and from SRNS. The reduction of pro-inflammatory lipid mediators during remission in SSNS children supports their potential as biomarkers of disease activity and treatment response for INS patients. Future longitudinal studies are needed to verify the prognostic value of these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.